Teflaro ceftaroline regulatory update

FDA approved an NDA from Forest for Teflaro ceftaroline to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA). In September, an FDA panel was unanimous that ceftaroline was a safe and effective treatment (see BioCentury, Sept. 13). ...